Birth outcome in women with breast cancer, cutaneous malignant melanoma, or Hodgkin’s disease: a review

Vivian Langagergaard
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Background: Data on birth outcome in women diagnosed with cancer before, during, or shortly after pregnancy are very sparse. The purpose of this review was to summarize the existing epidemiologic evidence of the adverse effect of breast cancer, cutaneous malignant melanoma, and Hodgkin’s disease on birth outcome.

Methods: The MEDLINE database was used to review the literature systematically. Studies that examined the following outcomes were included: preterm birth, low birth weight, low birth weight at term, stillbirths, congenital abnormalities, male proportion of newborns, and mean birth weight. Studies were grouped according to whether the woman had been diagnosed with the specific cancer before, during, or shortly after pregnancy.

Results: Few data exist on birth outcome in women with breast cancer, melanoma, or Hodgkin’s disease. The overall results from the limited number of studies, which included a comparison group for birth outcome, were reassuring. However, for women diagnosed with breast cancer before pregnancy, the only 2 studies that included comparison groups for birth outcome had conflicting results regarding the risk of preterm birth and congenital abnormalities. Furthermore, a recent cohort study of birth outcome in women who were diagnosed with Hodgkin’s disease before pregnancy indicated a slightly increased risk of congenital abnormalities among the newborns.

Conclusion: Overall, the existing studies offer reassuring results concerning the risks of adverse birth outcome for women diagnosed with breast cancer, melanoma, or Hodgkin’s disease before, during or shortly after pregnancy. A limitation of most studies was the imprecise risk estimates caused by the small number of adverse birth outcomes and the lack of results stratified by treatment. Therefore, international collaboration is necessary in the future, to obtain more precise risk estimates for adverse birth outcomes, and to allow stratified analyses according to, for example, treatment.

Keywords: epidemiology, breast cancer, melanoma, Hodgkin’s disease, birth outcome

Introduction

In Western countries women often postpone childbearing for personal or professional reasons.1 The average age of Danish women at their first delivery has gradually increased from 23 years in the 1960s to 29 years in 2008.2 Because the incidence rates of most cancers increase with advancing age3 more women can be expected to be diagnosed with cancer before childbearing, during pregnancy, or shortly after giving birth.

In Denmark, the most common malignancy affecting women of childbearing age is breast cancer, and the second most common one is cutaneous malignant melanoma (excluding nonmelanoma skin cancer).3 Hodgkin’s disease, whose incidence peaks in early adulthood and thus also affects women of childbearing age, belongs to cancers...
with a good prognosis. While in previous decades pregnancy in patients with a history of cancer was discouraged, currently such pregnancies are treated with more optimism, partly owing to the improved prognosis for several cancers, and partly because pregnancies subsequent to breast cancer, for example, do not seem to adversely affect maternal life expectancy. Because of a growing population of young cancer survivors, however, concerns have been raised about the adverse effects of cancer and cancer therapy on the offspring of the treated individuals. Offspring include those conceived after completion of treatment, and fetuses exposed to cancer therapy in utero. Data on birth outcome in women diagnosed with cancer before, during, or shortly after pregnancy are very sparse. Thus the purpose of this review was to summarize the existing epidemiologic evidence of the adverse effect of breast cancer, cutaneous malignant melanoma, and Hodgkin’s disease on birth outcome.

**Incidence of breast cancer, cutaneous malignant melanoma, and Hodgkin’s disease in women of childbearing age**

**Breast cancer**

Breast cancer is the most common female cancer in Denmark with more than 4000 women diagnosed every year (approximately 400 women are younger than 45 years of age at the time of diagnosis). The age-standardized incidence rate of breast cancer has almost doubled over the last 4 decades, but this increase is mainly confined to women aged between 45 and 75 years. The incidence of breast cancer in pregnancy is unknown, but is estimated to range from 1 in 3000 to 1 in 10,000 pregnancies.

**Cutaneous malignant melanoma**

For decades, the incidence of cutaneous malignant melanoma has been rising in most white populations around the world. In Denmark, the incidence of melanoma for women aged 15 to 34 years increased, on average, by 4.3% annually from 1970 to 1999, and in recent years, approximately 270 Danish women younger than 45 years have been diagnosed annually with melanoma. It has been estimated that melanoma represents approximately 8% of malignancies diagnosed during pregnancy.

**Hodgkin’s disease**

Hodgkin’s disease is characterized by a bimodal age incidence curve, with the first peak in young adults and the second in old-age groups. While age standardized incidence of Hodgkin’s disease has been declining slightly over time, the true incidence in older age groups has in fact decreased substantially, whilst among young adults in industrialized countries increases have been documented. In 2000, 29 women younger than 45 years of age were diagnosed with Hodgkin’s disease in Denmark. Hodgkin’s disease during pregnancy has a reported incidence ranging from 1 per 100,000 to 1 per 6000 deliveries.

**Definition of birth outcomes**

This review focuses on the prevalence of specific birth outcomes for children of cancer patients. It does not examine the risk of spontaneous or induced abortions, or diseases diagnosed later in life. The birth outcomes examined are defined below:

**Preterm birth**

Preterm birth is defined as delivery before 37 completed weeks of gestation. The time of delivery depends both on the natural course of the pregnancy and on clinical interventions, which may either shorten or prolong gestation. Given this mixture of spontaneous events and effects of medical interventions, the outcome of preterm birth itself is heterogeneous.

**Low birth weight**

Low birth weight (LBW) is defined as birth weight of less than 2500 g. Children in this group represent a mix of newborns whose growth is suboptimal, newborns delivered early, and newborns who are small for genetic reasons. As an alternative, some studies use “LBW at term” (defined as birth weight less than 2500 g in those born at least 37 weeks after conception), which suggests that the child remains small despite having had adequate time for growth. The presumption is that a child with LBW at term is likely to be growth retarded.

**Stillbirth**

In Denmark stillbirth is defined as antepartum or intrapartum fetal death after 22 completed weeks of pregnancy. Before 2004 only fetal deaths after 28 completed weeks of pregnancy were considered stillbirths.

**Congenital abnormalities**

Congenital abnormalities occur in 3% to 5% of all livebirths. However, each individual type of congenital abnormality is rare, with the most common occurring in about 1/1000 live births.
2 to 8 weeks post-conception, but the recognition of the abnormality may not occur until later in pregnancy (during ultrasound evaluation), at birth, in early childhood, or in adulthood, or the abnormality may never be recognized.

Male proportion of newborns
Approximately 51% of live-born children in Denmark are boys.

Methods
The epidemiologic evidence of the possible adverse effect of maternal breast cancer, melanoma, and Hodgkin’s disease on birth outcome was examined via a systematic literature review, including studies published before January 2010.

To review the literature, I searched the MEDLINE database and used the MeSH (Medical Subject Heading) terms “breast neoplasms”, “melanoma”, and “Hodgkin disease” [MAJR] (Major Topic headings only), respectively, in combination with “pregnancy” [MAJR], limiting the search to include only studies on human females, in English, and with an abstract. More studies were identified through communication with other researchers and by reviewing the reference lists of relevant articles. Studies were classified as case-series, if they reported birth outcome in a cohort of women with cancer without comparing it with the outcome of a comparison group. However, if the authors computed risk estimates for adverse birth outcome in comparison with the general population, the study was classified as a cohort study.

The studies listed in Tables 1, 2, and 3 were selected according to these criteria: studies of birth outcome in women who were diagnosed with breast cancer, melanoma, or Hodgkin’s disease at any time before pregnancy (including childhood), during pregnancy, or within 2 years after delivery were included. I selected only studies that examined preterm birth, LBW (or LBW at term), stillbirths, congenital abnormalities, male proportion of newborns, and/or mean birth weight. I excluded studies that reported overall risks of adverse birth outcome for survivors of different cancers combined. In addition, I excluded reviews, case-reports, case-series, and comments from the tables. However, given that the overall evidence on the topic is sparse, there are some references to case-series in the text.

Results
Below is a summary of the existing epidemiologic evidence of the adverse effect of maternal breast cancer, melanoma, and Hodgkin’s disease on birth outcome. The studies of birth outcome in women with, respectively, breast cancer, melanoma, and Hodgkin’s disease (Tables 1, 2, and 3) were selected according to the inclusion criteria described under Methods. No case-control study fulfilled the inclusion criteria.

Birth outcome in women with breast cancer
Data on birth outcome in women diagnosed with breast cancer before pregnancy are very sparse. Small case series have reported births of healthy children to women who became pregnant after being diagnosed with breast cancer. The only 2 studies with a comparison group for birth outcome that have been published, however, had conflicting results on the risk of preterm birth and congenital abnormalities after breast cancer (Table 1). In a registry-based cohort study from Sweden, Dalberg et al examined 331 births from 1973 to 2002, to women who were diagnosed with breast cancer before pregnancy. Dalberg et al found that a large majority of these births were free of adverse events, and reported no increased risk of stillbirth or reduced birth weight for gestational age. However, the study also reported an increased risk of very preterm birth (<32 weeks) (odds ratio [OR] = 3.2; 95% confidence interval [95% CI]: 1.7–6.0) and LBW (<1500 g) (OR = 2.9; 95% CI: 1.4–5.8) and an increased risk of congenital abnormalities (OR = 1.7; 95% CI: 1.1–2.5) among children of breast cancer survivors, compared with the general population. The increased risk of congenital abnormalities was seen especially in the births occurring in 1988 to 2002 (OR = 2.1; 95% CI: 1.2–3.7), which the authors explained by an increased use of chemotherapy in younger patients. The study, however, had no data on the treatment of women with breast cancer. In contrast, a nationwide Danish cohort study of 216 newborns of women diagnosed with breast cancer before pregnancy found no increased risk with respect to preterm birth, LBW at term, stillbirth, and congenital abnormalities as well as mean birth weight, compared with the outcomes of 33,443 births from unaffected mothers, and with results unaltered by stratification by a treatment variable. As suggested by Dalberg et al the different results in the Swedish and the Danish cohorts may be caused by different degrees of misclassification of the outcome variables between the registries or differences in the use of adjuvant radiotherapy or systemic treatments after breast cancer.

The Danish cohort study also observed an 8-fold increased risk of preterm delivery among 37 women diagnosed with breast cancer during pregnancy, which reflected a higher rate of elective early delivery, probably to allow an early start to cancer therapy. After adjustment for gestational
<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Period of cancer diagnosis</th>
<th>Design</th>
<th>Number</th>
<th>Adjustment</th>
<th>Relative effect estimates</th>
<th>Results for birth outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Langagergaard et al, 1943–2002 Denmark 2006</td>
<td>Cohort study: Births by cancer free women matched by time of birth and by county of mother’s residence</td>
<td>216 births by women with previous breast cancer</td>
<td>Yes, maternal age, parity, and calendar period of birth. PORs for CA and mean BW were also adjusted for gestational age</td>
<td>POR for preterm birth, LBW at term, stillbirth, and CAs</td>
<td>Stillbirths: none Mean BW = 3411 g vs 3474 g in controls. Proportion of male newborns = 50% vs 52% in controls, difference = –2.2% (95% CI: –8.9; 4.5)</td>
<td></td>
</tr>
<tr>
<td>Dalberg et al, 2006 Sweden</td>
<td>Cohort study: Birth outcome in the general population</td>
<td>331 births by women with previous breast cancer</td>
<td>Yes, maternal age, parity, and year of delivery</td>
<td>OR for preterm birth (&lt;32 wk and 32–36 wk), stillbirth, LBW (&lt;1500 g and 1500–2499 g), CAs, and SGA</td>
<td>Stillbirths: none Mean BW = 3411 g vs 3474 g in controls. Proportion of male newborns = 50% vs 52% in controls, difference = –2.2% (95% CI: –8.9; 4.5)</td>
<td></td>
</tr>
<tr>
<td>Zemlickis et al, 1958–1987 Canada 1992</td>
<td>Cohort study: Births of age-matched women exposed to nonteratogenic drugs in pregnancy</td>
<td>85 births by 118 women who were pregnant no earlier than 9 months before and no later than 3 months after their first treatment</td>
<td>Yes, maternal age (by matching) and mean BW was adjusted for GA</td>
<td>No</td>
<td>Lower mean BW (P = 0.02) Shorter mean GA (P = 0.01) Higher proportion of preterm births (P = 0.003) Mean BW = 3010 g vs 3451 g in controls Mean GA = 38.3 wk vs 39.4 wk in controls Preterm births = 26.7% Stillbirths = 2.4% CAs = none OR very LBW = 2.0 (95% CI: 1.0–4.1) OR preterm birth = 2.2 (95% CI: 1.7–2.8)</td>
<td></td>
</tr>
<tr>
<td>Smith et al, 1992–1997 USA 2001</td>
<td>Cohort study: Comparison group not specified</td>
<td>423 women who were diagnosed from 9 months preceding delivery until 12 months after delivery</td>
<td>Yes, maternal age</td>
<td>No</td>
<td>OR for preterm birth and very LBW</td>
<td></td>
</tr>
<tr>
<td>Langagergaard et al, 2006 Denmark</td>
<td>Cohort study: Births by cancer free women matched by time of birth and by county of mother’s residence</td>
<td>37 births of women diagnosed during pregnancy and 442 births of women diagnosed within 2 years after delivery</td>
<td>Yes, maternal age, parity, and calendar period of birth</td>
<td>POR for preterm birth, LBW at term, stillbirth, and CAs</td>
<td>Women diagnosed during pregnancy: POR preterm birth = 8.1 (95% CI: 3.8–1.7) (10 of 12 preterm deliveries were induced) POR LBW at term = 5.3 (95% CI: 0.6–5.1) POR CAs = 0.5 (95% CI: 0.1–3.6) Stillbirths: none Mean BW = 2948 g vs 3472 g in controls. Proportion of male newborns = 49% vs 52% in controls, difference = –3.4% (95% CI: –20; 13).</td>
<td></td>
</tr>
</tbody>
</table>
Birth outcome in women with cancer diagnosed within 2 years after delivery:

- **POR preterm birth**: OR = 1.4 (95% CI: 1.0–2.0)
- **POR LBW at term**: OR = 1.4 (95% CI: 0.7–2.8)
- **POR CAs**: OR = 1.1 (95% CI: 0.6–1.8)

Stillbirths: none

Mean BW: newborns of women diagnosed with breast cancer during pregnancy was 3471 g vs 3466 g in controls.

Proportion of male newborns: 53% vs 51% in controls, difference = 2.5% (95% CI: –2.2; 7.2)

Abbreviations: BW, birth weight; CAs, congenital abnormalities; CI, confidence interval; GA, gestational age; LBW, low birth weight; OR, odds ratio; POR, prevalence odds ratios; RR, relative risk; SGA, small for gestational age.

At age 442, there was a 240 g reduction (95% CI: -404; -76) in mean birth weight for newborns of women diagnosed with breast cancer during pregnancy. Furthermore, the study showed a tendency towards an increased risk of preterm birth for 442 women diagnosed with breast cancer within 2 years after delivery. The study found no increased risk of stillbirth or congenital abnormalities in women diagnosed with breast cancer during pregnancy or within 2 years of delivery.

These findings corroborate the results of 2 earlier cohort studies of birth outcome in women with breast cancer diagnosed during or shortly after pregnancy (Table 1). In these studies, however, the authors did not distinguish between birth outcome in women diagnosed with breast cancer during pregnancy and women diagnosed shortly after pregnancy. Smith et al identified 423 cases of breast cancer diagnosed from 9 months preceding delivery until 12 months after delivery over a period of 6 years in California. After adjusting the analyses for maternal age, the authors reported an OR of 2.2 (95% CI: 1.7–2.8) for preterm birth, and an OR of 2.0 (95% CI: 1.0–4.1) for very low birth weight. The study concluded that the data were consistent with an obstetric practice involving elective early delivery for cancer patients. Likewise, a historical cohort study of 118 women, who were pregnant within 9 months before or 3 months after their first treatment for breast cancer, reported a higher proportion of preterm births among offspring of women with breast cancer compared with controls, mainly because elective cesarean sections were done more often to allow earlier start to cancer therapy. In that study, only 2 stillbirths and no congenital abnormalities were observed. The authors also reported a lower mean birth weight after adjustment for gestational age.

Three case-series of 24, 28, and 29 pregnant breast cancer patients, respectively, have reported that chemotherapeutic treatment in the second and third trimester caused no congenital abnormalities or other complications, except for intrauterine growth retardation (IUGR) in 1 case.

Only 1 study examined the sex ratio among newborns and found no substantial differences in proportions of boys born to breast cancer patients compared with cancer-free mothers. Thus, the findings did not corroborate a theory of psychological stress (caused by a cancer diagnosis) or potential mutagenic exposure (from chemotherapy or radiation) reducing the male proportion of newborns. These findings are in line with earlier studies that examined the sex ratio for newborns of childhood cancer survivors and found no significant alterations.
### Table 2: Studies of birth outcome in women with cutaneous malignant melanoma

<table>
<thead>
<tr>
<th>Author</th>
<th>Country</th>
<th>Year</th>
<th>Period of cancer diagnosis</th>
<th>Design</th>
<th>Number</th>
<th>Adjustment</th>
<th>Relative effect estimates</th>
<th>Results for birth outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CMM diagnosed before pregnancy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Langagergaard et al</td>
<td>Denmark</td>
<td>2007</td>
<td>1970–2002</td>
<td>Cohort study</td>
<td>620</td>
<td>Yes, maternal age, parity, and calendar period of birth Mean BW was also adjusted for gestational age</td>
<td>POR for preterm birth, LBW at term, stillbirth, and CAs</td>
<td>POR&lt;sub&gt;preterm birth&lt;/sub&gt; = 1.1 (95% CI: 0.8–1.6) POR&lt;sub&gt;LBW at term&lt;/sub&gt; = 1.1 (95% CI: 0.6–2.0) POR&lt;sub&gt;stillbirth&lt;/sub&gt; = 1.2 (95% CI: 0.8–2.0) Stillbirths: none No difference in mean BW Proportion of male newborns = 53.2% vs 51.7% in controls difference = 1.5% (95% CI: –2.5; 5.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comparison: births of cancer free women matched by time of birth and by county of mother’s residence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CMM diagnosed during or shortly after pregnancy</strong></td>
<td></td>
<td></td>
<td></td>
<td>Cohort study</td>
<td>18</td>
<td>Yes, maternal age (by matching)</td>
<td>No</td>
<td>Lower mean birth weight (P = 0.15) No difference in mean GA (P = 0.53) Mean birth weight = 3036 g vs 3392 g in controls Mean GA = 39.5 wk vs 40.1 wk in controls Stillbirths = 5.6% CAs = 5.6%</td>
</tr>
<tr>
<td>Ravid et al&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Canada</td>
<td>1996</td>
<td>Not stated, but over a period of 30 years</td>
<td>Cohort study</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comparison: births of women diagnosed during pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O’Meara et al&lt;sup&gt;35&lt;/sup&gt;</td>
<td>USA</td>
<td>2005</td>
<td>1991–1999</td>
<td>Cohort study</td>
<td>149</td>
<td>Yes, maternal age and race OR for preterm birth and LBW</td>
<td></td>
<td>Women diagnosed during pregnancy: OR&lt;sub&gt;LBW&lt;/sub&gt; = 0.8 (95% CI: 0.3–1.8) OR&lt;sub&gt;preterm birth&lt;/sub&gt; = 0.9 (95% CI: 0.5–1.6) Stillbirths: none</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comparison: births by melanoma free women</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Langagergaard et al</td>
<td>Denmark</td>
<td>2007</td>
<td>1970–2002</td>
<td>Cohort study</td>
<td>88</td>
<td>Yes, maternal age, parity, and calendar period of birth Mean BW was also adjusted for gestational age</td>
<td>POR for preterm birth, LBW at term, stillbirth, and CAs</td>
<td>POR&lt;sub&gt;preterm birth&lt;/sub&gt; = 0.2 (95% CI: 0.03–1.5) POR&lt;sub&gt;LBW at term&lt;/sub&gt; = 0.6 (95% CI: 0.1–4.5) POR&lt;sub&gt;stillbirth&lt;/sub&gt; = 0.6 (95% CI: 0.2–2.7) Stillbirths: none Higher mean BW (difference = 88 g (95% CI: –18; 194)) Proportion of male newborns = 56.8% vs 51.9% in controls difference = 4.9% (95% CI: –5.5; 15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comparison: births of cancer free women matched by time of birth and by county of mother’s residence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BW, birth weight; CAs, congenital abnormalities; CI, confidence interval; CMM, cutaneous malignant melanoma; GA, gestational age; LBW, low birth weight; OR, odds ratio; POR, prevalence odds ratio; RR, relative risk; SGA, small for gestational age.
Table 3 Studies of birth outcome in women with Hodgkin’s disease

<table>
<thead>
<tr>
<th>Author and Country</th>
<th>Period of cancer diagnosis</th>
<th>Design</th>
<th>Number</th>
<th>Adjustment</th>
<th>Relative effect estimates</th>
<th>Results for birth outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hodgkin’s disease diagnosed before pregnancy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holmes and Holmes</td>
<td>1944–1975</td>
<td>Cohort study</td>
<td>52 births by 29 women with a history of Hodgkin’s disease</td>
<td>No</td>
<td>No</td>
<td>No overall increase in risk of abnormal birth outcome (stillbirth and CA combined) ($P = 1.00$)</td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1978</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janov et al</td>
<td>1966–1986</td>
<td>Cohort study</td>
<td>15 births by women with previous Hodgkin’s disease</td>
<td>No</td>
<td>RR for LBW</td>
<td>RR$_{LBW} = 2.5$ (95% CI: 0.3–9.0)</td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swerdlow et al</td>
<td>1970–1991</td>
<td>Cohort study</td>
<td>49 births by 16 women with previous Hodgkin’s disease and by wives of 11 men with a history of Hodgkin’s disease</td>
<td>No</td>
<td>RR for preterm birth, LBW, and male sex in newborn</td>
<td>RR$_{preterm} = 0.88$ (95% CI: 0.32–2.46)</td>
</tr>
<tr>
<td>UK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Green et al</td>
<td>1970–1986</td>
<td>Cohort study</td>
<td>729 births by women with childhood Hodgkin’s disease</td>
<td>Yes, maternal age, smoking, alcohol use and education</td>
<td>RR for stillbirth</td>
<td>RR$_{stillbirth} = 1.6$ (95% CI: 0.64–4.03)</td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signorello et al</td>
<td>1970–1996</td>
<td>Cohort study</td>
<td>337 births by women with childhood Hodgkin’s disease</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Langagergaard et al</td>
<td>1970–2002</td>
<td>Cohort study</td>
<td>192 births by women with previous Hodgkin’s disease</td>
<td>Yes, maternal age, parity, and calendar period of birth, LBW at term, stillbirth, and CAs</td>
<td>POR for preterm birth</td>
<td>POR$_{preterm birth, LBW, stillbirth, and CAs}$ = 1.7 (95% CI: 0.9–3.1)</td>
</tr>
<tr>
<td>Denmark</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hodgkin’s disease diagnosed during or shortly after pregnancy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lishner et al</td>
<td>1958–1984</td>
<td>Cohort study</td>
<td>40 births by 48 women who were pregnant no earlier than 9 months before and no later than 3 months after their first treatment</td>
<td>Yes, maternal age (by matching)</td>
<td>No</td>
<td>No difference in mean BW (P = 0.7), mean GA (P = 0.3), or stillbirths (P = 0.08)</td>
</tr>
<tr>
<td>Canada</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(Continued)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Country</td>
<td>Period of cancer diagnosis</td>
<td>Design</td>
<td>Number</td>
<td>Adjustment</td>
<td>Relative effect estimates</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------</td>
<td>----------------------------</td>
<td>--------------------------------</td>
<td>--------</td>
<td>------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Janov et al</td>
<td>USA</td>
<td>1966–1986</td>
<td>Cohort study</td>
<td>10 births by women who were pregnant from 12 months before diagnosis until end of treatment</td>
<td>No</td>
<td>RR for LBW</td>
</tr>
<tr>
<td>Smith et al</td>
<td>USA</td>
<td>1992–1997</td>
<td>Cohort study</td>
<td>172 births by women who were diagnosed from 9 months before until delivery</td>
<td>Yes, maternal age</td>
<td>OR for prematurity and very LBW</td>
</tr>
<tr>
<td>Langagergaard et al</td>
<td>Denmark</td>
<td>1970–2002</td>
<td>Cohort study</td>
<td>15 births by women diagnosed during pregnancy and 85 births by women diagnosed within 2 years after delivery</td>
<td>Yes, maternal age, parity, and calendar period of birth. Mean BW was also adjusted for gestational age</td>
<td>POR for preterm birth and CAs</td>
</tr>
</tbody>
</table>

Women diagnosed within 2 years after delivery:

POR<sub>preterm birth</sub> = 1.2 (95% CI: 0.5–2.9) POR<sub>CAs</sub> = 1.6 (95% CI: 0.6–4.5) LBW at term: none Stillbirths: none No difference in mean BW Proportion of male newborns = 61.2% vs 51.4%, difference = 9.8% (95% CI: –0.7; 20.3)

Abbreviations: BW, birth weight; CAs, congenital abnormalities; CI, confidence interval; GA, gestational age; LBW, low birth weight; OR, odds ratio; POR, prevalence odds ratios; RR, relative risk.
In conclusion, the overall results regarding the birth outcome among women with breast cancer are reassuring. However, additional studies of birth outcome in women who were diagnosed with breast cancer before pregnancy are needed to resolve the discrepancy between the findings of the Danish \(^{23}\) and the Swedish \(^{24}\) study.

**Birth outcome in women with cutaneous malignant melanoma**

A nationwide cohort study from Denmark (Table 2) found no excess risk with respect to preterm birth, LBW at term, stillbirth, and congenital abnormalities among 620 newborns of women who were diagnosed with melanoma before pregnancy or 88 newborns of women who were diagnosed during pregnancy, compared with, respectively, 29,788 and 4180 newborns of cancer free women.\(^{34}\) Furthermore, there was no important difference in mean birth weight or male proportion of newborns between women with melanoma and comparison women. However, the study reported a prevalence odds ratio (POR) of 4.6 (95% CI: 1.7–12.3) for stillbirth among 351 newborns of women, who were diagnosed with melanoma within 2 years after the time of delivery. This finding, which was unexpected, has not been shown by other studies, and may have been a chance finding.

Two other cohort studies have examined birth outcome in offspring of women diagnosed with melanoma during or shortly after pregnancy (Table 2).\(^{35,36}\) In a hospital-based cohort study of 18 deliveries by women diagnosed with melanoma during pregnancy over a period of 30 years, there were 17 live births and 1 anencephalic stillbirth.\(^{36}\) The newborns of women with melanoma had a lower mean birth weight than newborns of women without cancer, but there was no difference in mean gestational age. The authors suggested that the differences in birth weight were due to IUGR secondary to the melanoma, its therapies, or its complications. In that study, however, mean birth weights were based on only 9 melanoma-exposed newborns and 9 newborns of age-matched comparison mothers.

In a population-based cohort study, O’Meara et al identified 149 women diagnosed with melanoma during pregnancy and 263 women diagnosed within 12 months after delivery over a period of 9 years in California.\(^{35}\) That study and the Danish study\(^ {34}\) were in agreement with respect to the findings of no increased risk of preterm birth or low birth weight among newborns of mothers with melanoma. For women diagnosed during pregnancy, O’Meara and colleagues reported an OR of 0.9 (95% CI: 0.5–1.6) for preterm birth and an OR of 0.8 (95% CI: 0.3–1.8) for LBW, adjusted for age and race. They found no fetal deaths in the exposed group and no increased risk of adverse birth outcome in women diagnosed with melanoma in the first postpartum year. The study did not examine the risk of congenital abnormalities among newborns.

The overall results from these studies show no substantially increased risk of adverse birth outcome for women with melanoma, with the possible exception of an increased risk of stillbirth for newborns of women diagnosed within 2 years of delivery.

**Birth outcome in women with Hodgkin’s disease**

More studies have examined birth outcome in women with previous Hodgkin’s disease. Janov et al did not find any substantial increased risk of LBW and no congenital abnormalities among newborns of 15 women with prepregnancy Hodgkin’s disease compared with the general population (Table 3).\(^ {37}\) Likewise, Swerdlow et al reported no increased risk of preterm birth, LBW, stillbirth, or congenital abnormalities among 49 children of 16 women and 11 men who had previously been treated for Hodgkin’s disease compared with the general population (Table 3).\(^ {38}\) Another study, which compared 52 births by 29 women previously treated for Hodgkin’s disease with births by the women’s siblings, found no overall increased risk of congenital abnormalities and stillbirths combined among children of Hodgkin’s disease patients. The study also found no association of birth outcome with radiotherapy alone (supra- or infradiaphragmatic), whereas women treated with both chemotherapy and radiation were more likely to give birth to an abnormal child (\(P = 0.047\)) (Table 3). The 3 studies, however, were all based on small study populations and did not control for potential confounders.

Recently, a large cohort study of female survivors of childhood cancer found that 19.2% of 337 women with childhood Hodgkin’s disease had a preterm birth compared with 12.6% among sibling controls (Table 3).\(^ {40}\) Another study reported 11 stillbirths among 729 births of female survivors of childhood Hodgkin’s disease, corresponding to a relative risk of 1.6 (95% CI: 0.64–4.03) (Table 3).\(^ {41}\) In contrast, a recent Danish cohort study of birth outcome in women with previous Hodgkin’s disease found no increased risk of preterm birth and only 1 stillbirth among 192 women, of whom more than 75% had been diagnosed with Hodgkin’s disease in adulthood (≥20 years of age at diagnosis) (Table 3).\(^ {42}\) The results from the Danish study, however, indicated a slightly increased risk of congenital abnormalities among newborns of women with previous Hodgkin’s
disease \((\text{POR} = 1.7; 95\% \text{ CI: 0.9–3.1})\). Furthermore, it was reported, that the POR for congenital abnormalities increased with calendar time of Hodgkin’s disease diagnosis (ie, for 1991–2000 the POR was 3.1 \((95\% \text{ CI: 1.4–6.9})\) compared with \(\text{POR} = 1.0\) (reference) for 1970–1980).\(^{42}\)

The Danish study also reported increased risk estimates for congenital abnormalities among newborns of women who were diagnosed with Hodgkin’s disease during or shortly after pregnancy, but these estimates were based on few outcomes and were therefore imprecise. However, it is important to emphasize that teratogens increase the rate of specific, rather than all abnormalities, and the study was unable to evaluate those.

Two studies reported an increased risk of preterm birth for women diagnosed with Hodgkin’s disease during pregnancy, which reflected a higher rate of elective early delivery (Table 3).\(^{18,42}\) In contrast, a historical cohort study by Lishner et al which included 40 births by women who were pregnant between 9 months before and 3 months after their first treatment for Hodgkin’s disease, reported no increased risk of preterm birth or induced deliveries (Table 3).\(^{19}\) Furthermore, the study indicated no difference in mean birth weight compared with controls, while the proportion of stillbirths was not statistically different from that of the general population. The study reported 1 child with a congenital abnormality born to the only patient treated with chemotherapy in the first trimester.

There was no evidence of any substantial decrease in the male proportion of newborns among women diagnosed with Hodgkin’s disease before pregnancy, indicating that earlier treatment for Hodgkin’s disease is not a risk factor for early male abortion.\(^{42}\)

For newborns of women diagnosed with Hodgkin’s disease during pregnancy, there was an increase in the male proportion, compared with newborns of comparison mothers, which was surprising and could have been a chance finding.\(^{42}\)

In conclusion, the overall results are reassuring regarding the risks of adverse birth outcome for women with Hodgkin’s disease, although the possibility of an increased risk of congenital abnormalities in newborns of women diagnosed with Hodgkin’s disease before pregnancy cannot be ruled out.

**Discussion**

**Possible adverse effects of cancer and cancer therapy on birth outcome**

When cancer is diagnosed in pregnancy, there is often a conflict between optimal maternal therapy and fetal well-being.\(^3\) The benefit of the diagnostic work-up, surgery, radiotherapy and chemotherapy must be weighed carefully against the risk to the fetus.\(^{12}\) Under these circumstances, preterm labor is often induced as soon as the fetus becomes viable, in order to allow amplification of therapy.\(^{12}\)

The rationale for examining birth outcome in women diagnosed with cancer within a few years after delivery is that pregnancies starting before the diagnosis may be affected by the preclinical cancer. A Swedish study, which compared observed to expected rates of cancer during pregnancy and during the first year after delivery, suggested that diagnosis is often delayed to the postpartum period.\(^{43}\) A possible explanation for this delay could be that unusual signs and symptoms may be ascribed to the pregnancy rather than the cancer.

For women who retain or regain fertility after cancer treatment, an issue of great importance is their ability to carry a pregnancy to term and give birth to a normal child. Chemotherapy and radiotherapy may affect future pregnancies in cancer survivors by directly affecting the reproductive tract or by causing mutations in germ cells.\(^{39}\) It is therefore important to establish the magnitude of an increased risk (if any) of adverse birth outcomes such as preterm birth, LBW (or LBW at term), stillbirth, and congenital abnormalities.

**Possible adverse effects of the cancer itself on birth outcome**

Little is known about exact mechanisms whereby maternal cancer may pose risk to a developing fetus. In theory, several factors might influence the fetus if the mother has malignant disease:

- It has been proposed that the cancer may alter metabolism and distribution of hormones and vitamins, some of which are determinants for certain congenital abnormalities.\(^{44}\)
- Cancer patients have an increased tendency to suffer from febrile illness,\(^5\) and maternal fever in early pregnancy has been associated with stillbirth\(^{45}\) and congenital abnormalities.\(^{45,46}\)
- Malnutrition is more frequent in the patients. Maternal undernutrition during pregnancy resulting in reduced transfer of nutrients to the fetus may cause fetal undernutrition and intrauterine growth retardation.\(^{47}\) Impaired fetal growth is strongly associated with neonatal morbidity and mortality,\(^{48}\) and may also be associated with diseases later in life.\(^{49}\)
- Psychological stress related to severe life events (eg, a cancer diagnosis) around the time of conception may reduce the male proportion of newborns through differential conception or differential abortion of male embryos.\(^{29}\)
Likewise, some studies have reported associations of stress in pregnancy with preterm delivery,\(^5\) and congenital abnormalities.\(^1\)\(^9\)\(^,\)\(^5\)\(^5\)\(^–\)\(^5\)\(^7\)

**Possible adverse effects of specific cancer therapy on birth outcome**

**Surgery**

Most surgical interventions can be safely undertaken with minimum risk during pregnancy, although there is almost always some element of maternal–fetal conflict.\(^5\)\(^3\)

**Radiation**

Radiation is commonly used for cancer diagnosis and treatment. The fetus is sensitive to ionizing radiation, with the brain being the most sensitive organ.\(^5\)\(^4\) During the peri-implantation and immediate post-implantation periods, radiation has an all or nothing effect, resulting in either embryonic death or further normal development. Later in pregnancy, radiation may cause congenital abnormalities, IUGR, mental retardation, or childhood cancer.\(^5\)\(^4\) As a result, the general recommendation is to postpone radiotherapy until after delivery.\(^1\)\(^2\) At the same time, births of healthy children after radiotherapy of pregnant women for breast cancer and supradiaphragmatic Hodgkin’s disease have been reported (with appropriate shielding of the fetus).\(^1\)\(^9\)\(^,\)\(^5\)\(^5\)\(^–\)\(^5\)\(^7\)

In nonpregnant women of childbearing age, ionizing radiation may damage ovarian function, cause premature ovarian failure, or trigger germ cell mutations, which can lead to congenital abnormalities in future offspring.\(^3\)\(^0\)

Studies of women exposed to the atomic-bomb radiation and their subsequently conceived offspring have indicated a higher rate of spontaneous abortion, but showed no increase in the risk of major congenital abnormalities compared with the children of women from the general population.\(^1\)\(^0\) These results corroborate studies of childhood cancer survivors reporting no increased risk of congenital abnormalities or genetic diseases in the offspring of women exposed to pre-gestational radiotherapy.\(^5\)\(^8\)\(^–\)\(^5\)\(^1\)

It has also been postulated that maternal gonadal exposure to radiation would decrease the male proportion of newborns by inducing recessive sex-linked lethal mutations.\(^5\)\(^2\)

In addition, women previously treated with high-dose abdominal radiotherapy have been found to have an increased risk of spontaneous abortions,\(^4\)\(^1\)\(^3\)\(^,\)\(^6\)\(^4\) preterm deliveries,\(^4\)\(^0\) and LBW infants\(^5\)\(^8\)\(^,\)\(^3\)\(^9\)\(^,\)\(^6\)\(^3\) during subsequent pregnancies. These effects are most likely due to radiation-induced damage to the women’s abdominopelvic structures.\(^1\)\(^0\)\(^,\)\(^5\)\(^9\)

Traditional ways to protect the ovaries against the radiation damage are shielding of the ovaries and, in case of pelvic lymph node irradiation, repositioning of the ovaries out of the radiation field (oopheropexy).\(^6\)\(^5\) Today, many young patients needing radiotherapy (or chemotherapy) are offered the option of cryopreservation of their ovarian tissue, while recent studies of ovarian tissue autotransplantation offer promising results.\(^5\)\(^6\)

**Chemotherapy**

A potential teratogenic effect of chemotherapy during pregnancy depends on the agent used, the timing of exposure, the dose, and the characteristics affecting placental transfer.

Use of chemotherapy during the first trimester increases the risk of miscarriage and congenital abnormalities.\(^2\)\(^6\) A review of 139 cases of first-trimester exposure to chemotherapy reported a total of 24 (17%) infants with congenital abnormalities after a single agent exposure, and a prevalence of 25% after combination-agent exposure.\(^5\)\(^7\)

Chemotherapy during the second and third trimesters may increase the risk of preterm birth, IUGR, and stillbirth.\(^1\)\(^2\) Furthermore, the central nervous system continues to develop after the first trimester, which makes it sensitive to insults during the entire pregnancy.\(^1\)\(^2\) While exposure to chemotherapy after the first trimester does not cause macroscopic anatomical defects, it may have long-term subanatomical consequences, for example, by interfering with the neuronal proliferation and migration.\(^1\)\(^2\) However, a study of late side effects among 84 children whose mothers received chemotherapy, during pregnancy, for hematological malignancies did not show impairments in learning behavior, or neurological abnormalities after a median follow-up of 18 years.\(^6\)\(^8\) Given all the evidence, it is generally recommended that chemotherapy is delayed until after the first trimester.\(^1\)\(^2\)

In nonpregnant women of childbearing age, chemotherapy can adversely affect fertility.\(^5\)\(^9\) Damage to the ovarian tissue depends on the agent used, the dose, and the age of the patient at treatment.\(^7\)\(^0\) Furthermore, chemotherapy is potentially mutagenic\(^1\)\(^0\) with animal studies showing that it can cause mutations in oocytes and increase the risk of fetal abnormalities.\(^5\)\(^5\)

**Endocrine therapy**

The use of anti-estrogenic therapy, such as tamoxifen, in pregnant breast cancer patients has been discouraged because of teratogenic effects seen in animal models.\(^1\)\(^2\) Direct evidence for teratogenesis in humans is limited, with only isolated reports of rare forms of congenital abnormalities associated with tamoxifen use.\(^7\)\(^1\)
Conclusions and perspectives
This review summarizes the existing epidemiologic evidence of the adverse effect of maternal breast cancer, melanoma, and Hodgkin’s disease on birth outcome. On the whole, existing studies offer reassuring results concerning the risks of adverse birth outcome for women diagnosed with breast cancer, melanoma, or Hodgkin’s disease, before, during, or shortly after pregnancy. However, a limitation of most studies was the imprecise risk estimates caused by the small number of adverse birth outcomes and the lack of results stratified by treatment. Since even nationwide data may be sparse, an international collaboration is required in order to assemble data on a sufficient number of births by women with cancer in order to obtain more precise risk estimates for adverse birth outcomes. Moreover, a larger number of birth outcomes would allow stratified analyses according to, for example, different treatment regimens, stages, and how close in time the cancer diagnosis was to pregnancy. Information on these clinical details could be obtained from hospital medical records and clinical databases.

Very few studies document the long-term follow-up of children exposed to maternal cancer and cancer treatment in utero. Maternal cancer may affect not only birth outcome, but also long-term health, as a consequence of intra-uterine programming. Thus, large cohort studies with long term follow-up are needed to evaluate the entire spectrum of adverse effects of cancer or cancer treatment on offspring of the patients.

Disclosure
The contents of this review have previously been included in a PhD thesis.

References
Clinical Epidemiology downloaded from https://www.dovepress.com/ by 54.70.40.11 on 08-Jan-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)


